# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disea...
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrol...
Oppenheimer analyst Leland Gershell maintains NuCana (NASDAQ:NCNA) with a Outperform and lowers the price target from $150 t...